Primary Sclerosing Cholangitis: Diagnostic and Management Strategies
Diagnosis
For patients with cholestatic biochemistry, MRCP should be the primary diagnostic imaging modality, with typical cholangiographic features sufficient for diagnosis without routine liver biopsy 1. The diagnosis requires cholestatic liver biochemistry (elevated alkaline phosphatase and GGT) combined with characteristic bile duct stricturing on imaging, after excluding secondary causes of sclerosing cholangitis 2.
Diagnostic Algorithm:
- Initial imaging: MRCP is first-line (non-invasive, high sensitivity/specificity) 1
- ERCP reserved for: Tissue acquisition when malignancy suspected OR therapeutic intervention needed 1
- Liver biopsy indicated only when:
Measure serum IgG4 levels in all suspected PSC cases to exclude IgG4-associated sclerosing cholangitis, which is steroid-responsive and requires different management 2, 1.
Medical Management
Ursodeoxycholic acid (UDCA) should NOT be used for routine treatment of PSC 1. This is a strong recommendation from the most recent 2019 BSG guidelines based on high-quality evidence showing no benefit for transplant-free survival or cancer prevention 1.
Corticosteroids and immunosuppressants are NOT indicated for classic PSC 1. They should only be used in overlap syndromes with AIH features or confirmed IgG4-SC 1.
Symptom Management:
- Pruritus: Cholestyramine first-line; rifampicin and naltrexone second-line 1
- Fatigue: Actively investigate and treat alternative causes 1
Surveillance and Screening
Mandatory Surveillance:
Colonoscopy:
Gallbladder: Annual ultrasound for polyp surveillance 1
Varices: Screen for esophageal varices per international guidelines when cirrhosis/portal hypertension present 1
Osteoporosis: Bone density examination at diagnosis, then every 2-3 years 2, 1
- Treat with calcium 1.0-1.5g and vitamin D 1,000 IU daily if osteopenia present 2
Hepatocellular carcinoma: Surveillance per international guidelines if cirrhosis present 1
Management of Dominant Strictures
Dominant strictures (≤1.5mm in common bile duct or ≤1mm in hepatic duct) occur in 45-58% of patients and require prompt intervention 2. These strictures always raise suspicion for cholangiocarcinoma, though most are benign 2.
Indications for ERCP:
- Rising bilirubin and/or worsening pruritus
- Progressive bile duct dilatation on imaging
- Cholangitis
- New or changing symptoms 2, 1
ERCP Protocol:
Before any ERCP, patients must receive prophylactic antibiotics 1.
Mandatory pathological sampling (brush cytology/biopsy) of all suspicious strictures before therapeutic intervention to exclude cholangiocarcinoma 2, 1.
Balloon dilatation is preferred over biliary stenting 1. The 2019 BSG guidelines strongly recommend this based on moderate-quality evidence showing lower risk of bacterial cholangitis with balloon dilatation 1.
Management of Complications:
- Bacterial cholangitis: Antimicrobial therapy PLUS correction of bile duct obstruction 2
- Recurrent cholangitis: Long-term prophylactic antibiotics 2
- Refractory cholangitis: Evaluate for liver transplantation 2
Cholangiocarcinoma Detection
CA19-9 has low diagnostic accuracy and routine measurement is NOT recommended for surveillance 1. When cholangiocarcinoma is clinically suspected:
- Immediate specialist MDM referral 1
- Contrast-enhanced cross-sectional imaging (CT/MRI) for diagnosis and staging 1
- Tissue diagnosis via: ERCP brush cytology/FISH/endobiliary biopsy/cholangioscopy/EUS-guided biopsy 1
The 10-15% lifetime risk of cholangiocarcinoma is a major mortality driver, but early detection remains challenging 2, 3.
Liver Transplantation
PSC is a well-recognized indication for liver transplantation with improving long-term outcomes 1. Assess eligibility per national guidelines when:
- End-stage liver disease/decompensation
- Refractory bacterial cholangitis 2
- Intractable symptoms despite optimal management
Common pitfall: Recurrent PSC occurs in up to 25-38% of transplant recipients 3, 4, requiring continued surveillance post-transplant.
Follow-Up Structure
All PSC patients require lifelong follow-up due to unpredictable disease course and serious complications 1.
- Symptomatic/evolving/complex disease: Expert multidisciplinary assessment 1
- Early stable disease: Can be managed in general clinics 1
- New/changing symptoms or lab abnormalities: MRCP, dynamic liver MRI, and/or contrast CT 1
Patients meeting trial inclusion criteria should be offered referral to centers participating in clinical trials 1, as no approved medical therapy currently improves transplant-free survival 1, 4.